Are patients with familial hypercholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project

Annals of Clinical Biochemistry

Volumn 45, Issue 2, 2008, Pages 199-205

  Hadfield, S G ^a   Horara, S ^a   Starr, B J ^a   Yazdgerdi, S ^a   Bhatnagar, D ^b   Cramb, R ^c   Egan, S ^d   Everdell, R ^d   Ferns, G ^e   Jones, A ^f   Marenah, C B ^g   Marples, J ^h   Prinsloo, P ^g   Sneyd, A ^g   Stewart, M F ⁱ   Sandle, L ^j   Wang, T ^e,k   Watson, M S ^e   Humphries, S E ^l  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL OLDHAM HOSPITAL   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^e ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^h ROYAL ALBERT EDWARD INFIRMARY   (United Kingdom)

ⁱ HOPE HOSPITAL   (United Kingdom)

^j TRAFFORD GENERAL HOSPITAL   (United Kingdom)

^k FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^l ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATINE DERIVATIVE;

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PEDIGREE; PRIORITY JOURNAL; RELATIVE; UNITED KINGDOM;

AMBULATORY CARE FACILITIES; CHOLESTEROL, LDL; ENGLAND; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MEDICAL AUDIT; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PHYSICIANS, FAMILY;

EID: 44249091844     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2007.007078     Document Type: Article

References (27)

1. Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000;321:148
2. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969;2:1380-2
3. Marks D, Thorogood M, Farrer JM, Humphries SE. Census of clinics providing specialist lipid services in the United Kingdom. J Public Health (Oxf) 2004;26:353-4
4. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81
5. Betteridge DJ, Broome K, Durrington PN, et al. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Athereosclerosis 1999;142:105-12
6. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis 1993;104:1-18
7. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6
8. Scientific Steering Committee on behalf of the Simon Broome Register Group. The risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303:893-6
9. Heath KE, Humphries SE, Middleton-Price H, Boxer M. A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. Eur J Hum Genet 2001;9:244-52
10. Graham CA, McIlhatton BP, Kirk CW, et al. Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. Atherosclerosis 2005;182:331-40
11. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006;43:943-9
12. Marks D, Wonderling D, Thorogood M, et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002;324:1303
13. Bhatnagar D, Morgan J, Siddiq S, et al. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 2000;321:1497-500
14. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001;357:165-8
15. Department of Health. Department of Health: Our Inheritance, our Future: Realising the Potential of Genetics in the NHS, 2003. London: The Stationery Office
16. Campbell JP, Maxey VA, Watson WA. Hawthorne effect: implications for prehospital research. Ann Emerg Med 1995;26:590-4
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of low density lipoprotein cholesterol without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
18. Heiberg A. The lipoprotein and lipid pattern in xanthomatosis. Acta Med Scand 1975;198:183-95
19. Civeira F, Castillo S, Alonso R, et al. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation. Arterioscler Thromb Vasc Biol 2005;25:1960-5
20. Humphries SE, Cranston T, Allen M, et al. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med 2006;84:203-14
21. Heath KE, Gudnason V, Humphries SE, Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 1999;143:41-54
22. Thompson GR, Maher VM, Matthews S, et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-16
23. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90
24. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 2004;350:1579-82
25. Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004;148:447-55
26. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):1-52
27. Marks D, Thorogood M, Neil SM, Humphries SE, Neil HA. Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes. J Med Screen 2006;13:156-9